Non-Viral Transfection Reagents Market Industry Trends And Forecasts To 2035: Patents, Partnerships, And Big Pharma Initiatives Accelerate Non-Viral Transfection Reagents Market Growth

(MENAFN- GlobeNewsWire - Nasdaq) The non-viral transfection reagents market presents growth opportunities driven by the demand for cost-effective, low-immunogenicity alternatives to viral vectors, particularly for nucleic acid-based therapies. North America leads the market, with emerging growth in Asia-Pacific. Research and clinical applications, and partnerships, are key focus areas.

Dublin, Sept. 26, 2025 (GLOBE NEWSWIRE) -- The "Non-Viral Transfection Reagents Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Non-Viral Transfection Method, Application Areas, End-User, and Key Geographical Regions" report has been added to ResearchAndMarkets's offering.

The global non-viral transfection reagents market valued at USD 633 million in 2025, is projected to grow at a CAGR of 8.0% during the forecast period, till 2035.

Over the years, a large number of nucleic acid-based therapies have gained regulatory approval, underscoring both their therapeutic potential and rising popularity. As a result, there has been an increased demand for vectors capable of efficiently delivering these therapies. Notably, transfection is one such process of artificially introducing genetic material / nucleic acid into the cells with the use of specific carriers / vectors. However, conventional transfection through viral vectors poses several challenges, such as complications related to immunogenicity and cytotoxicity along with being a cost-intensive development process.

Consequently, the demand for alternative gene drug vehicles such as non-viral transfection reagents has increased. The non-viral transfection reagents can overcome limitations, such as inflammation and non-specific transduction, associated with viral vectors. Further, these vectors are significantly cost effective than their virus-based counterparts, implying the potential for use in the development of more affordable products in the gene therapy market.

In non-viral transfection method, the gene transfer to cells may involve either direct introduction of DNA into the host cell, or the delivery of carrier gene by a complex formation with lipids, polymers or lipo-polymers. In both cases, gene sequences are inserted into a plasmid (vector) for its expression within the host. Due to low immunogenicity, non-viral transfection systems allow re-dosing of genetic material without the risk of complications. Moreover, such reagents are more economical than viral vectors as they can be easily produced in large quantities.

Non-Viral Transfection Reagents Market: Key Insights

The report delves into the current state of the non-viral transfection reagents market and identifies potential growth opportunities within industry.

Some key findings from the report include:

• Over 185 non-viral transfection reagents are currently available in the market; of these, ~60% use lipid-based carriers to enable the transfection of genetic material.
• In pursuit of building a competitive edge, industry stakeholders are actively enhancing their respective offerings to comply with the evolving industry benchmarks.
• Over 20 electroporation-based systems and more than 35 other non-viral transfection systems have been developed for the delivery of DNA, RNA and protein fragments, in different types of cells.
• Developers are focused on the integration of advanced features in their respective systems, in order to maintain their competitive position in the market.
• The current market landscape of non-viral transfection and reagent developers features the presence of both established and emerging players, located across key global regions.

• A notable increase in published scientific literature related to non-viral transfection methods and techniques has been observed in the past few years.
• In the past four years, around 870 patents have been filed / granted related to non-viral transfection methods; of these, over 60% of the patents were by non-academic players.
• Foreseeing a lucrative potential, big pharma players have also undertaken several initiatives focused on non-viral transfection; notably, all collaborations inked by such players in the past two years were focused on preclinical operations.
• In order to optimize the price of advanced therapies, innovators are anticipated to forge alliances with non-viral transfection reagent and system developers.
• Cost is a key determinant for the adoption of non-viral transfection techniques; the pricing strategy framework is likely to assist players in evaluating competitive prices for their reagents.
• The market is likely to witness an annual growth of 8%; the projected opportunity is expected to be well distributed across different transfection methods, application areas, end-users and key geographical regions

Key Players in the Non-Viral Transfection Reagents Market, Profiled in the Report Include:

• Altogen Biosystems
• Bio-Rad Laboratories
• BEX
• BTX
• Celsion
• Genprex
• Inovio Pharmaceuticals
• MaxCyte
• MilliporeSigma
• Nepa Gene
• OZ Biosciences
• Thermo Fisher Scientific

Non-Viral Transfection Reagents Market: Research Coverage

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global non-viral transfection reagents market, focusing on key market segments, including type of non-viral transfection method, application areas, end-user and key geographical regions.
• Non-Viral Transfection Reagents Market Landscape: A comprehensive evaluation of the companies developing non-viral transfection reagents.
• Electroporation-Based Transfection Systems Market Landscape: A detailed analysis of the companies developing electroporation-based non-viral transfection systems. Additionally, a comprehensive evaluation of electroporation transfection systems developers.
• Other Non-Viral Transfection Systems Market Landscape: An insightful evaluation of the companies developing other non-viral transfection systems. Additionally, a comprehensive evaluation of other non-viral transfection systems developers.
• Company Competitiveness Analysis: A comprehensive competitive analysis of non-viral transfection reagent and system developers, examining factors, such as developer strength and product portfolio strength.
• Technology Competitiveness Analysis: A detailed analysis of electroporation transfection systems and other non-viral transfection systems, examining factors, such as developer strength and product portfolio strength.
• Company Profiles: In-depth profiles of key players that are engaged in the development of non-viral transfection reagents and systems, focusing on overview of the company, financial information and recent developments and an informed future outlook.
• Potential Strategic Partners: An insightful analysis of more than 80 cell and gene therapy developers that are likely to partner with non-viral transfection reagent and system developers, based on several relevant parameters, such as pipeline maturity, developer strength, pipeline strength and type of therapy.
• Benchmark Analysis: A comprehensive benchmark analysis of various non-viral focused initiatives undertaken by big pharma players.
• Patent Analysis: An in-depth analysis of patents filed / granted till date in the non-viral transfection systems domain, based on various relevant parameters, such as type of patent, publication year, application year, geography, type of applicant, CPC symbols, emerging focus areas, leading players, patent benchmarking and valuation analysis.
• Publication Analysis: An insightful analysis of over 450 peer-reviewed, scientific articles focused on non-viral transfection reagents and systems, based on various relevant parameters, such as year of publication, type of publication, type of molecule delivered, target therapeutic area, key focus areas, popular cells and cell lines. Additionally, the section includes analysis of the leading publishers across different geographies and key journals.
• Pricing Strategy Framework: A detailed framework for analyzing the pricing strategy of a company's non-viral transfection reagents and its competitive market position, including an equation to estimate reagent prices based on their characteristics.

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. NON-VIRAL TRANSFECTION REAGENTS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. List of Non-Viral Transfection Reagents
4.3 List of Non-Viral Transfection Reagent Developers

5. ELECTROPORATION-BASED TRANSFECTION SYSTEMS: MARKET LANDSCAPE
5.1. Chapter Overview
5.2. List of Electroporation-based Transfection Systems
5.3. List of Electroporation-based Transfection System Developers

6. OTHER NON-VIRAL TRANSFECTION SYSTEMS: MARKET LANDSCAPE
6.1. Chapter Overview
6.2. List of Other Non-Viral Transfection Systems
6.3. List of Other Non-Viral Transfection System Developers

7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Methodology and Key Parameters
7.3. Non-Viral Transfection Reagent Developers: Company Competitiveness Analysis

8. TECHNOLOGY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Methodology and Key Parameters
8.3. Electroporation-based Transfection Systems: Technology Competitiveness Analysis
8.4. Other Non-Viral Transfection Systems: Technology Competitiveness Analysis

9. COMPANY PROFILES

Non-Viral Transfection Reagent Developers

• MilliporeSigma
• OZ Biosciences
• Thermo Fisher Scientific

Electroporation-based Transfection System Developers

• BEX
• Bio-Rad Laboratories
• BTX (A subsidiary of Harvard Bioscience)
• MaxCyte
• NepaGene

Other Non-Viral Transfection System Developers

• Imunon (Formerly known as Celsion)
• Genprex
• Inovio Pharmaceuticals

10. POTENTIAL STRATEGIC PARTNERS

11. BIG PHARMA INITIATIVES
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. None-Viral Transfection Reagents and System Developers: Big Pharma Initiatives

12. PATENT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Non-Viral Transfection Reagents and Systems: Patent Analysis
12.4. Non-Viral Transfection Reagents and Systems: Patent Benchmarking Analysis
12.5. Non-Viral Transfection Reagents and Systems: Patent Valuation Analysis

13. PUBLICATION ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Non-Viral Transfection Reagents and Systems: Recent Publications
13.4. Analysis by Year of Publication
13.5. Analysis by Type of Publication
13.6. Analysis by Type of Molecule Delivered
13.7. Analysis by Target Therapeutic Area
13.8. Analysis by Key Focus Areas (Word Cloud Representation)
13.9. Analysis by Prominent Cells and Cell Lines (Word Cloud Representation)
13.10 Leading Publishers: Analysis by Number of Publications
13.11. Prominent Journals: Analysis by Number of Publications
13.12. Prominent Copyright Holders: Analysis by Number of Publications
13.13 Key Funding Institutes: Analysis by Number of Publications

14. PRICING STRATEGY FRAMEWORK

15. MARKET SIZING AND OPPORTUNITY ANALYSIS

16. EXECUTIVE INSIGHTS

17. CONCLUSION

18. APPENDIX I: TABULATED DATA

19. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachments

• Non-Viral Transfection Reagent Distribution
• List of Transfection Reagents
• Market Distribution

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN26092025004107003653ID1110115991